Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13038653 | 0.77 | NR3C1 (0.36) | NR3C1 | |
| SCHEMBL27276531 | 0.74 | NPSR1 (0.40) | — | |
| SCHEMBL6428923 | 0.74 | NR3C1 (0.35) | NR3C1 | |
| SCHEMBL12424411 | 0.71 | KCNA3 (0.43) | — | |
| SCHEMBL12424459 | 0.71 | — | — | |
| SCHEMBL23155994 | 0.71 | NR3C1 (0.39) | NR3C1 | |
| SCHEMBL3271980 | 0.70 | NR3C1 (0.34) | NR3C1 | |
| SCHEMBL14553530 | 0.69 | — | — | |
| SCHEMBL3690441 | 0.69 | HTR2A (0.39) | NR3C1 | |
| SCHEMBL24952559 | 0.69 | SIGMAR1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029540-B1 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC (US) | 2010-08-04 | — | — | EP | disclosed |
| EP-2029540-B1 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC (US) | 2010-08-04 | — | — | EP | disclosed |
| US-7659287-B2 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659287-B2 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659287-B2 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. (US) | 2010-02-09 | — | — | US | disclosed |
| EP-2029540-A2 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | Amgen Inc. (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20070299111-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299111-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299111-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007145834-A2 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007145834-A2 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299111-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | HSD17B1, HSD3B1, HSD11B1 | NR3C1 216/4885OPRM1 2700/4885OPRL1 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.